AstraZeneca is in talks over a potential merger with U.S. rival Bristol Myers Squibb in a deal reported at around $400 billion, according to the Financial Times.
Key facts
- AstraZeneca is considering a merger with Bristol Myers Squibb, per FT reporting.
- The potential deal has been reported at around $400 billion.
- AstraZeneca is a U.K.-based pharmaceutical company; Bristol Myers Squibb is a U.S. rival.
- The report was carried by CNBC on August 2, 2026.
AstraZeneca, the U.K.-based pharmaceutical giant, is considering a deal to merge with its U.S. rival Bristol Myers Squibb, according to reporting from the Financial Times relayed by CNBC.
The potential tie-up has been described as a roughly $400 billion megadeal, which would rank among the largest transactions ever attempted in the pharmaceutical industry.
AstraZeneca is one of Britain’s largest listed companies, while Bristol Myers Squibb is a major U.S. drugmaker, making any combination a significant cross-border transaction between two of the sector’s leading players.
At this stage the discussions are described as being at the consideration stage, and no agreement has been confirmed by either company. Details on the structure, timing or terms of any potential deal were not provided in the report.
CNBC published the report on August 2, 2026, attributing the underlying account to the Financial Times.
Because talks of this nature can change or collapse before any formal announcement, the reported figures and intentions remain preliminary until confirmed by the companies involved.
Why it matters
A merger of this scale would reshape the global pharmaceutical landscape, bringing together two major drugmakers across the U.K. and U.S. For patients, investors and employees, a deal reported at around $400 billion could have wide-ranging effects on drug development, competition and market power.
Frequently asked questions
How much is the reported AstraZeneca–Bristol Myers Squibb deal worth?
The potential merger has been reported at around $400 billion, according to the Financial Times as relayed by CNBC.
Has the merger been confirmed?
No. The reporting describes AstraZeneca as considering a deal, and no agreement has been confirmed by either company.
Which companies are involved?
U.K. pharmaceutical giant AstraZeneca and its U.S. rival Bristol Myers Squibb.